20.500.12556/DiRROS-9223 Imunoterapija : nova zdravila, drugačni sopojavi Imunotherapy : new drugs, different adverse events Imunoterapija je v zadnjih letih postala eden izmed pomembnih načinov sistemskega zdravljenja bolnikov z rakom. Priča smo bili različnim imunskim strategijam, med temi je tudi inhibicija kontrolnih točk. Zdravila proti CTLA-4, PD-1 in PD-L1 so protitelesa proti zaviralcem kontrolnih točk, ki lahko povišajo imunsko aktivnost proti rakavim celicam in tako ojačajo imunski odgovor proti raku. Večja uporaba teh zdravil pa je privedla do pojava posebne vrste imunsko pogojenih neželenih učinkov. Ti se najpogosteje izrazijo na koži, črevesju, žlezah z notranjim izločanjem, pljučih in mišično-skeletnem sistemu, lahko pa je prizadet kateri koli organ. Večina imunsko pogojenih neželenih učinkov je blagih do zmernih, v literaturi pa obstajajo poročila o hudih in življenje ogrožajočih. Pomembna je njihova zgodnja prepoznava in zdravljenje, kakor tudi multidisciplinaren pristop, da preprečimo resne zaplete. Over the past years, immunotherapy has become an important systemic treatment strategy for cancer patients. We have seen multiple different strategies, and checkpoint blockade is one them. Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), and programmed death-ligand 1 (PD-L1) are antibodies against checkpoint inhibitors that can increase immune activity against cancer, thus making the immune system stronger against cancer cells. However, the increasing use of these agents has exposed a discrete group of immune-related adverse events (irAEs). Skin, gut, endocrine, lung, and musculoskeletal irAEs are the most common, although every organ can be affected. The majority of irAEs are mild to moderate in severity, however, serious and life-threatening irAEs are reported in literature. Early detection and treatment of irAEs is important, and a multidisciplinary approach is sometimes needed to prevent serious consequences. imunoterapija zaviralci kontrolnih točk neželeni učinki immunotherapy checkpoints inhibitors adverse events true false true Slovenski jezik Angleški jezik by Authors Neznano 2018-10-26 11:02:41 2018-10-26 11:06:51 2022-08-14 03:36:05 0000-00-00 00:00:00 2018 0 0 str. 18-22 št. 1 Letn. 22 jun. 2018 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 1408-1741 10.25670/oi2018-003on 2990715 65324032 RAZ_Ovcaricek_Tanja_i2018.pdf RAZ_Ovcaricek_Tanja_i2018.pdf 1 07BA677BAB7A48AC4704776D61D4728B fd058076940a66dfdbcb0295bbf32be9e07a5e3aa953d17fb7e8d616551cd2f7 782a51a7-17b5-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=10995 Onkološki inštitut Ljubljana Onkologija : strokovni časopis za zdravnike 0 0 0